The Food and Drug Administration is taking formal steps to lift compounding restrictions on peptides. This abrupt policy shift is driven by a massive gray market of untested overseas imports and public pressure from Health and Human Services Secretary Robert F. Kennedy Jr.
The FDA’s Pharmacy Compounding Advisory Committee scheduled a public meeting for July 23–24, 2026. The panel will review seven specific peptides for conditions like obesity, insomnia, and ulcerative colitis. Five more peptides will face review by the end of February 2027.
Kennedy is a self-professed “big fan” of the injectables. He argued on social media that removing restrictions will “restore regulated access” for patients. He claims this will shift consumer demand away from dangerous black-market suppliers in China.
Public health experts are pushing back. Former FDA officials and scientists, including UC Davis Professor Paul Knoepfler, warn that many of these short chains of amino acids lack rigorous clinical trial data. According to an investigation by the Associated Press, the unknown safety risks pose a severe threat to the American public.
The wellness industry is watching closely. The policy reversal stands to massively benefit telehealth companies operating in the health space. Hims & Hers Health (HIMS) strategically acquired a California-based peptide manufacturing facility in early 2025. This allowed the company to vertically integrate its personalized medication supply chain just ahead of this regulatory shift.
What the Peptide Reversal Means for Telehealth Pharmacies
This move is a stark reversal of a 2023 FDA policy under the Biden administration. That previous policy aggressively added 19 peptides, including the popular BPC-157, to a restricted “high-risk” list due to potential cancer, heart, and kidney risks.
Former FDA officials like Dr. Janet Woodcock warn this reversal is a massive paradigm shift. This upends the agency’s 1962 mandate requiring thorough clinical efficacy and safety studies before a drug goes to market.
As detailed in a report from ProPublica, clearing compounding pharmacies to produce these drugs legally changes the market structure. It shifts millions of dollars away from gray-market vendors and directly into the balance sheets of public telehealth firms like HIMS.